Shut Down

Lodo Therapeutics Stock

Lodo Therapeutics is a drug discovery and development company.

Sign up today and learn more about Lodo Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Lodo Therapeutics Stock

Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health: resistant infectious disease and cancers. Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources. Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.

Funding History

January 2016$17.0M



Sean Brady

Co-Founder & Interim Chief Scientific Officer

David Pompliano

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: